Skip to main content

Table 4 Comparison of clinicopathological characteristics of 255 HER2-positive patients without trastuzumab

From: Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

FactorsGroup 1p-value
 Low pre-NLRHigh pre-NLR
Age (year)
  ≤ 4014 (11.0)17 (13.3)0.581
  > 40113 (89.0)111 (86.7) 
T stage
 T129 (22.8)22 (17.2) 
 T282 (64.6)90 (70.3)0.515
 T3–416 (12.6)16 (12.5) 
N stage
 pN068 (53.5)76 (59.4) 
 pN141 (32.3)35 (27.3)0.624
 pN2–318 (14.2)17 (13.3) 
Histological grade
 1~298 (77.2)100 (78.1)0.854
 329 (22.8)28 (21.9) 
HR
 Negative72 (56.7)73 (57.0)0.957
 Positive55 (43.3)130 (43.0) 
Ki67 (%)
  < 3067 (52.8)57 (44.5)0.189
  ≥ 3060 (47.2)71 (55.5) 
NC
 No59 (46.5)58 (45.3)0.855
 Yes68 (53.5)70 (54.7) 
Total127 (100.0)128 (100.0) 
  1. NLR neutrophil/lymphocyte ratio, HR hormone receptor, NC neoadjuvant chemotherapy